Surgery Partners Inc. stock climbed in afternoon trading following an announcement that the company has placed binding signature pages into escrow for the sale of its ownership stakes in two Idaho hospital assets to Intermountain Health. The combined Idaho Falls facilities were valued at approximately $1.15 billion, and Surgery Partners is set to receive about $795 million in total consideration.
The news, disclosed via Globe Newswire on Friday morning, provided a clear, company-specific catalyst for the share move. Investors pushed the stock to a session high of $16.60 before it eased back to trade around $15.77 in the afternoon. The intraday advance represented roughly a 3.6% gain versus the prior close.
Alongside the sale announcement, Surgery Partners reiterated its full-year 2026 targets. The company maintained a revenue outlook between $3.35 billion and $3.45 billion and forecast Adjusted EBITDA of at least $530 million, explicitly excluding the financial impact of the Idaho transaction.
Management characterized the disposal as a deliberate element of portfolio optimization. CEO Eric Evans framed the move as a step to redeploy capital and operational focus toward the ambulatory surgery center market, which the company views as a higher-priority growth area. The company also made clear that physician ownership of Mountain View Hospital will remain unchanged, preserving the existing clinical partnerships tied to that facility.
The market backdrop offered little in the way of lift for the stock. The S&P 500 was essentially flat at -0.1% on the day while the NASDAQ traded lower by -0.8%, indicating that the uptick in Surgery Partners shares was driven primarily by the transaction news rather than broader equity market momentum.
Surgery Partners is scheduled to release its second-quarter results before the market opens on August 10, 2026. That earnings report will likely provide additional detail on near-term financial positioning and on how proceeds from the Idaho assets will be reflected in the company’s balance sheet and capital allocation plans.
Putting the move in context, the combination of a sizable asset sale, a substantial cash infusion and a reaffirmed 2026 outlook offered investors a tangible rationale to increase their bids for the shares. The stock is now trading well above its 52-week low of $11.41 but remains materially below its 52-week high of $24.10, leaving room on the upside contingent on execution and the company’s allocation of proceeds.
Key points
- Surgery Partners placed binding signature pages into escrow to sell interests in Mountain View and Idaho Falls Community Hospital to Intermountain Health for assets valued at about $1.15 billion, with Surgery Partners to receive roughly $795 million.
- The company reaffirmed its 2026 guidance: revenue of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million, excluding the transaction.
- The transaction is part of a portfolio optimization strategy aimed at reallocating capital and focus to ambulatory surgery centers; physician ownership at Mountain View Hospital will remain intact.
Risks and uncertainties
- The financial impact of the sale is excluded from the company’s reaffirmed 2026 outlook, leaving uncertainty about near-term reported results once the transaction is completed.
- The stock reaction was driven by company-specific news while broader markets were flat or weaker, indicating potential volatility if wider market conditions shift.
- Investors will likely look to the upcoming Q2 earnings report on August 10, 2026, for further clarity on how the divestiture will affect the balance sheet and capital allocation plans.